Just Biotherapeutics, Inc. Receives Grant To Develop Sequence Optimized Broadly Neutralizing Anti-HIV Antibodies for Low Cost Manufacture and Improved Stability

Share Article

Company will Receive up to $9.4M Over 4 Years From the Bill & Melinda Gates Foundation

Just, an organization dedicated to designing and applying innovative technologies to expand global access to biotherapeutics, today announced it has received additional funding from the Bill & Melinda Gates Foundation.

Under terms of the agreement, Just will receive up to $9.4M in funding over 4 years to develop sequence optimized broadly neutralizing anti-HIV antibodies for clinical evaluation. Building on the discovery efforts of several leading laboratories, partially funded by the Gates Foundation, Just will improve candidate molecules to lower the cost of manufacturing and to simplify distribution in low and middle-income countries by developing more stable therapeutics.

“Just will partner with some of the best laboratories in the field of HIV research, developing biologics for HIV prevention that could potentially reduce the spread of AIDS in low and middle-income countries,” said Jim Thomas, CEO of Just. “We are grateful for this exciting opportunity.”

About Just.
Founded in 2014, Just is led by an experienced team in the fields of protein, process and manufacturing sciences. The Just team came together to solve the scientific and technical hurdles that block access to life changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus and passion is to create access and value for a global market through scientific and technological innovation.

For more information, please visit http://www.justbiotherapeutics.com

Contact Information
Media Relations
media(at)justbiotherapeutics(dot)com
206-651-5094

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Media Relations
Visit website